Activity Dates: 04/20/2009 - 04/20/2012
This course is closed. Please look for other available products in CPNP University.
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.
Attention Deficit Hyperactivity Disorder is a common neuropsychiatric condition impacting 4.4% of the adult population age 18-44 according to a recent epidemiological survey. As in childhood, the condition is often marked by challenges with attention, organization and forgetfulness, although adults who were hyperactive as children often grow out of physical hyperactivity. There is evidence that ADHD is associated with poorer outcomes in domestic and occupational endeavors, as well as higher rates of motor vehicle accidents.
Assessment requires clinical evaluation of whether the patient meets criteria for the DSM-IV symptoms of ADHD, with adult manifestation. Comorbid mental health conditions are more common in individuals with ADHD, compounding the distress experienced by individuals with the condition. Prominent comorbid mental health conditions may require prioritized management.
Stimulant and non-stimulant pharmacologic interventions have demonstrated efficacy for ADHD management. These agents all share similar side effect patterns (physical discomforts and mild cardiovascular effects) and contraindications (particularly conditions that would be exacerbated by increased sympathetic nervous system activity). Tolerability of these agents is maximized by gradual dose increase, avoidance of other sympathomimetic agents, and trials as needed of different release patterns of an effective agent. Long-acting preparations are preferable to short acting agents due to ease of daylong coverage and evidence for higher rates of diversion or misuse of short acting agents. Adequacy of interventions is optimized by identifying treatment goals related to ADHD symptoms, and serial screening of symptoms. Data is emerging on non-pharmacologic interventions, including cognitive-behavioral approaches as adjuncts to pharmacotherapy interventions.
You will proceed through the following steps to satisfactorily complete this course:
This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.
Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows Vista and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Craig Surman, MDView biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-09-007-L01-P (1.0 contact hours).
ACPE approved contact hours are accepted for ANCC Certification Renewal (see pages 5 and 6): At least 50% (37.5 hours) of your 75 continuing education hours must be formally approved continuing education hours. Formally approved continuing education hours meet one or more of the criteria listed below:
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: Short and long acting methylphenidate in non-FDA approved doses, short and long-acting amphetamine preparations in non-FDA approved doses, atomoxetine in non-FDA approved doses, modafanil, desipramine, imipramine, clonidine, guanfacine in non-FDA approved indications.
This programming was supported in part by grants from Bristol-Myers Squibb, Forest Laboratories, Inc., Lilly, Schering-Plough, Cyberonics, Shire, and Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.